

Title (en)  
TREATMENT OF THROMBOSIS BY COMBINED USE OF A FACTOR XA INHIBITOR AND ASPIRIN, TISSUE PLASMINOGEN ACTIVATOR (TPA), A GPIIB/IIIA ANTAGONIST, LOW MOLECULAR WEIGHT HEPARIN OR HEPARIN

Title (de)  
BEHANDLUNG VON THROMBOSE MIT KOMBINATIONEN AUS FACTOR XA HEMMERN MIT ASPIRIN, GEWEBE-PLASMINOGENAKTIVATOREN (TPA), GPIIB/IIIA ANTAGONISTEN, NIEDERMOLEKULARE HEPARIN ODER HEPARIN

Title (fr)  
TRAITEMENT DE LA THROMBOSE AU MOYEN D'UNE COMBINAISON D'UN INHIBITEUR DU FACTEUR XA ET D'ASPIRINE, D'UN ACTIVATEUR TISSULAIRE DU PLASMINOGENE (TPA), D'UN ANTAGONISTE DE GPIIB/IIIA, D'HEPARINE A FAIBLE MASSE MOLECULAIRE OU D'HEPARINE

Publication  
**EP 1161279 A1 20011212 (EN)**

Application  
**EP 00913894 A 20000310**

Priority  
• US 0006451 W 20000310  
• US 12381599 P 19990311

Abstract (en)  
[origin: WO0053264A1] Provided is a method of treating thrombosis in mammals by administering therapeutically effective amounts of a combination of (i) a Factor Xa inhibitor, and (ii) a compound selected from the group consisting of aspirin, TPA, a GPIIb/IIIa antagonist, low molecular weight heparin and heparin, wherein the dose administered for at least one of (i) and (ii) is a subtherapeutic dose. Preferably, the combination of (i) and (ii) provides a synergistic effect.

IPC 1-7  
**A61P 7/02**; **A61P 9/12**; **A61K 31/715**; **A61K 45/06**; **A61K 38/49**; **A61K 38/02**; **A61K 31/42**; **A61K 31/60**

IPC 8 full level  
**A61K 31/19** (2006.01); **A61K 31/42** (2006.01); **A61K 31/44** (2006.01); **A61K 31/47** (2006.01); **A61K 31/60** (2006.01); **A61K 31/715** (2006.01); **A61K 38/02** (2006.01); **A61K 38/49** (2006.01); **A61K 45/06** (2006.01); **A61P 7/02** (2006.01); **A61P 9/12** (2006.01)

CPC (source: EP KR)  
**A61K 31/19** (2013.01 - EP); **A61K 31/42** (2013.01 - EP); **A61K 31/44** (2013.01 - EP); **A61K 31/47** (2013.01 - EP); **A61K 31/60** (2013.01 - EP); **A61K 31/715** (2013.01 - EP); **A61K 31/727** (2013.01 - KR); **A61K 38/02** (2013.01 - EP); **A61K 38/49** (2013.01 - EP); **A61K 45/06** (2013.01 - EP); **A61P 7/02** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)  
See references of WO 0053264A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0053264 A1 20000914**; AU 3525400 A 20000928; AU 766089 B2 20031009; BR 0010381 A 20020205; CA 2361650 A1 20000914; CN 1346292 A 20020424; EA 200100966 A1 20020228; EP 1161279 A1 20011212; IL 144798 A0 20020630; JP 2002538226 A 20021112; KR 20020005614 A 20020117; NZ 513217 A 20031128; ZA 200106360 B 20020802

DOCDB simple family (application)  
**US 0006451 W 20000310**; AU 3525400 A 20000310; BR 0010381 A 20000310; CA 2361650 A 20000310; CN 00804880 A 20000310; EA 200100966 A 20000310; EP 00913894 A 20000310; IL 14479800 A 20000310; JP 2000603752 A 20000310; KR 20017011454 A 20010910; NZ 51321700 A 20000310; ZA 200106360 A 20010802